INMED PHARMACEUTICALS INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
INMED PHARMACEUTICALS INC. (INM) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $187.22 thousand for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-23.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-11
- INMED PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00.
- INMED PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- INMED PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $187.22K.
- INMED PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $187.22K, a 80.67% decline from fiscal 2024.
- INMED PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $968.38K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $0.00 derived: sum of 2 quarters · filed 2025-09-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $187.22K 10-K · filed 2025-09-23 |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $187.22K 10-Q · filed 2025-05-12 | $187.22K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $187.22K 10-Q · filed 2026-02-11 | $187.22K derived: sum of 3 quarters · filed 2026-02-11 | $187.22K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $187.22K 10-Q · filed 2025-11-06 | $187.22K derived: sum of 2 quarters · filed 2025-11-06 | $187.22K derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $0.00 derived: sum of 2 quarters · filed 2025-09-23 | $968.38K 10-K · filed 2025-09-23 | |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $968.38K 10-Q · filed 2025-05-12 | ||
| 2023-12-31 | $968.38K 10-Q · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |